

Erratum to: Brodalumab: First Global Approval

Sarah L. Greig¹

Published online: 22 September 2016
© Springer International Publishing Switzerland 2016

Erratum to: Drugs (2016) 76(14):1403–1412
DOI 10.1007/s40265-016-0634-8

Page 1404, Section 1.1 Company Agreements

The first sentence, which previously read:

In October 2010, Kyowa Hakko Kirin acquired exclusive licensing rights from Amgen for the development and marketing of brodalumab in Japan and other Asian countries [8].

Should read:

In October 2010, Kyowa Hakko Kirin acquired exclusive licensing rights from Kirin-Amgen for the development and marketing of brodalumab in Japan and other Asian countries [8].

The online version of the original article can be found under
doi:[10.1007/s40265-016-0634-8](https://doi.org/10.1007/s40265-016-0634-8).

✉ Sarah L. Greig
dru@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754,
New Zealand